Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Covington
Moodys
Cantor Fitzgerald
Federal Trade Commission
Fuji
Mallinckrodt
Accenture
Queensland Health

Generated: December 12, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,017,927

« Back to Dashboard

Which drugs does patent 6,017,927 protect, and when does it expire?

Patent 6,017,927 protects VESICARE and is included in one NDA.

Protection for VESICARE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-two patent family members in twenty-two countries.

Summary for Patent: 6,017,927
Title: Quinuclidine derivatives and medicinal composition thereof
Abstract:Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same. ##STR1## The compound has an antagonistic effect on muscarinic M.sub.3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.
Inventor(s): Takeuchi; Makoto (Ibaraki, JP), Naito; Ryo (Ibaraki, JP), Hayakawa; Masahiko (Ibaraki, JP), Okamoto; Yoshinori (Ibaraki, JP), Yonetoku; Yasuhiro (Ibaraki, JP), Ikeda; Ken (Chiba, JP), Isomura; Yasuo (Ibaraki, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/860,377
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,017,927
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,017,927

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-001 Nov 19, 2004 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-002 Nov 19, 2004 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,017,927

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan6-327045Dec 28, 1994
PCT Information
PCT FiledDecember 27, 1995PCT Application Number:PCT/JP95/02713
PCT Publication Date:July 04, 1996PCT Publication Number: WO96/20194

International Family Members for US Patent 6,017,927

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 233761 ➤ Sign Up
Australia 4355396 ➤ Sign Up
Australia 695616 ➤ Sign Up
Canada 2208839 ➤ Sign Up
China 1045601 ➤ Sign Up
China 1171109 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Citi
Mallinckrodt
Cerilliant
McKinsey
Moodys
Covington
US Army
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.